Orthotopic Modeling for Preclinical Microenvironmental Fidelity

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 225 papers28 conceptsfrozen 2026-10-04

In cancer research, the subcutaneous xenograft—implanting human tumor cells under the skin of a mouse—has long been the workhorse of drug discovery. It is convenient, easy to monitor, and allows for simple measurements with a caliper. However, a growing body of evidence across diverse malignancies suggests that this convenience comes at a steep cost: the loss of "microenvironmental fidelity."

The central insight of recent research is that a tumor is not just a collection of malignant cells, but a complex ecosystem that behaves differently depending on its "soil." When we move a tumor from its native organ to the skin, we strip away the specific chemical gradients, mechanical stresses, and cellular neighbors that dictate how that tumor grows, invades, and responds to therapy.

The Soil Dictates the Seed

The most immediate problem with subcutaneous models is the absence of organ-specific signaling. In AURKA promotes angiogenesis in uveal melanoma via activation of the JAK2/STAT3/VEGFA signaling pathway, Qingyue Ma and colleagues argue that tumors originating in specialized tissues, like the eye, rely on site-specific vascular responses that the skin simply cannot replicate.

This discrepancy is even more pronounced in the brain. Zhe Li and Ruting Wei have shown that the unique physiological and chemical environment of the central nervous system is essential for studying glioblastoma. In ATXN3 deubiquitinates ZEB1 and facilitates epithelial–mesenchymal transition in glioblastoma, the researchers emphasize that the mechanisms of tumor invasion—how a cancer "drills" into healthy tissue—are fundamentally tied to the brain's specific architecture. Without an intracranial (orthotopic) model, findings regarding tumor spread may not translate to human patients.

Genetic and Metabolic Divergence

It is tempting to think that a cancer cell's behavior is hard-coded in its DNA, regardless of where it sits. However, Rui Han and Yong‐Guang Yang demonstrated in Different tumorigenicity and distinct metastasis and gene signature between orthotopic and subcutaneous neuroblastoma xenografted mice that the environment actually changes the "software" of the cell. They found that neuroblastoma cells implanted in the adrenal gland (the orthotopic site) showed significantly faster growth and higher expression of key oncogenes like PHOX2B compared to the same cells implanted subcutaneously.

Metabolism follows a similar pattern. In Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC, Elisabeth Bliemsrieder and Christian Hundshammer noted that subcutaneous models fail to capture the specific biochemical influences of the liver. This leads to metabolic profiles that differ from endogenous disease, potentially misleading researchers who are trying to target a tumor's "fuel" source.

Barriers to Delivery and Metastasis

Beyond signaling, the physical environment creates barriers that subcutaneous models ignore. Diya Zhang points out in Preclinical Experimental Models for Human Glioma that transplant-based models often lack a functional blood-brain barrier (BBB). This leads to an overestimation of drug efficacy; a compound might easily reach a tumor under the skin but fail to cross the BBB in a real-world clinical setting.

Similarly, the mechanics of metastasis—how a tumor hijacks blood vessels to spread—are difficult to study without the proper anatomical context. Lingling Guo argues in Metastasis of nasopharyngeal carcinoma: What we know and do not know that the absence of reliable orthotopic models limits our understanding of early invasion. Without the specific stroma and pressure of the primary site, the "vessel hijacking" seen in patients is rarely replicated in the lab.

Toward Modular and Integrated Platforms

The field is moving toward models that integrate these complex factors. Nicole Pandell and Jacob Househam recently introduced ProMPt: A modular preclinical platform for functional modelling of prostate cancer heterogeneity and therapeutic vulnerabilities. This platform uses organoids in an immunocompetent environment to bridge the gap between simple cell cultures and the complex human body.

By prioritizing orthotopic placement and microenvironmental fidelity, researchers like Yongfei He and Xin Chen are ensuring that the "breakthroughs" seen in mice have a much higher chance of becoming cures for humans. The shift reflects a fundamental realization: to understand the disease, you must respect the home it built for itself.

Papers in this version

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 22 papers
  2. Version 1 · 2026-10-04 · 25 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_orthotopic_model_fidelity_ff1a295b,
  title = {orthotopic model fidelity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/orthotopic-model-fidelity/rdr_ff1a295bac0042718cdea3303d4f911c},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}

This exact version (version 1, frozen text):

@misc{lacuna_orthotopic_modeling_for_preclinical_micr_ff1a295b_v1,
  title = {Orthotopic Modeling for Preclinical Microenvironmental Fidelity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/orthotopic-modeling-for-preclinical-microenvironmental-fidelity/rdr_ff1a295bac0042718cdea3303d4f911c/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-22},
}